Strong prediction of virological response to combination therapy by IL28B gene variants rs12979860 and rs8099917 in chronic hepatitis C genotype 4

Abstract

In CHC genotype 4 patients, favourable genotypes of both SNPs of IL28B are valuable for predicting SVR. Additional genotyping of rs8099917 in carriers of the heterozygous C allele of rs12979860 can improve the prediction of SVR.

Assessment of interleukin 28B genotype as a predictor of response to combined therapy with pegylated interferon plus ribavirin in HCV infected Egyptian patients

“…In the present study, 76 out of 153 patients (49.6%) achieved SVR which was comparable to previously reported studies [7,24,25]. The rs8099917 TT genotype was present in 94 patients (62%), TG genotype was present in 54 patients (35%) and GG genotype was present in only 5 patients (3%).…”

“…The rs8099917 TT genotype was present in 94 patients (62%), TG genotype was present in 54 patients (35%) and GG genotype was present in only 5 patients (3%). Similar frequencies of rs8099917 genotype distribution were observed by previous studies [24][25][26][27][28]. Carriers of the rs8099917 TT genotype (major allele) showed a higher rate of SVR compared to TG + GG (minor allele carriers) (74% vs. 26%, P = 0.004).…”

Hepatitis C genotype 4: The past, present, and future

“…The favorable CC phenotype is found in 20%30% of Egyptian patients with chronic HCV [141,142] . In Europe, SVR rates for HCV GT4 infected patients who are IL28B CC is > 80% [139,140,143] .…”

“…In Europe, SVR rates for HCV GT4 infected patients who are IL28B CC is > 80% [139,140,143] . In Egypt, CC patients had response rates between 67% and 87% [141,142] . Mutations in the NS5A region, particularly in patients with more than 6 aa mutations in the Interferon RBV resistance determining region (IRRDR) are highly associated with good response to PEGIFN and RBV combination therapy, while a less diverse (≤ 5) IRRDR sequence is associated with nonresponse [144146] .…”

Data Mining and Machine Learning Algorithms Using <i>IL28B</i> Genotype and Biochemical Markers Best Predicted Advanced Liver Fibrosis in Chronic Hepatitis C

“…It appeared to be the strongest factor associated with viral clearance, either spontaneously or after IFN-based therapy in genotypes 1, 2, 3, and 4 (5-10) and across different ethnic groups (11). In patient with G4, rs8099917 genotype in the carriers of the heterozygous C allele of rs12979860 was found to improve the prediction of sustained virologic response (SVR) (12). The IL28B genotype neither predicts nor affects the viral load in Egyptians with chronic HCV infections (13).…”